StockNews.AI
PHAR
StockNews.AI
69 days

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

1. Pharming's shareholders approved all proposals at the AGM on June 11, 2025. 2. Dr. Elaine Sullivan joins the Board, enhancing leadership in R&D. 3. Deloitte reappointed as auditors for 2025 financial year. 4. Share buyback and issuance authorization renewed by shareholders.

Earnings
-1.51%Current Return
VS
+0.4%S&P 500
$11.564906/11 09:14 PM EDTEvent Start
$11.3906/13 02:54 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The appointment of a notable industry leader could attract investment interest.

How important is it?

Strategic board changes indicate potential future performance improvements and operational continuity.

Why Long Term?

Consistent leadership and strategic direction foster confidence, affecting long-term valuation positively.

Related Companies

DeloitteNDAQPHARM
Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. Dr. Elaine Sullivan, a seasoned leader in the international pharmaceutical and biotech industry with deep R&D expertise and public non-executive board experience, was appointed to the Pharming Board of Directors, upon binding recommendation of the Board of Directors, for a period of four years (agenda item 3). Mrs. Jabine van der Meijs and Mr. Leonard Kruimer were reelected as Non-Executive Directors, upon binding recommendation of the Board of Directors, for a period of four years (agenda items 4.a and 4.b respectively). After six years of dedicated service to the company, Mrs. Deborah Jorn did not stand for re-election. In addition, Mr. Steven Baert, who served on the Board for four years, did not stand for re-election. On behalf of the Board, Richard Peters, Chairman, expressed his heartfelt gratitude to Deborah and Steven for their services and many valuable contributions. Shareholders also approved the proposals to reappoint Deloitte Accountants B.V. as the external auditor of the Company for the financial year 2025 (agenda item 5), to renew the authorizations for the Board of Directors to issue shares (agenda item 6) and to repurchase shares (agenda item 7). A recording of the webcast, presentation slides from today’s AGM, the voting results and more details regarding agenda items are available on the Company’s website under Investors/Shareholder Meetings. About Pharming Group N.V.Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn. Inside InformationThis press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. For further public information, contact:Pharming Group, Leiden, the NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E: investor@pharming.com FTI Consulting, London, UKSimon Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl Pharming AGM results press release 2025_EN_11JUN25

Related News